Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Specific Immunotherapy in Ovarian Cancer: A Systematic Review Publisher Pubmed



Alipour S1 ; Zoghi S1 ; Khalili N1 ; Hirbodmobarakeh A1, 2, 3 ; Emens LA4 ; Rezaei N2, 3, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Border of Immune Tolerance Education and Research Network (BITERN), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  2. 2. Molecular Immunology Research Center, Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Oncology, Kimmel Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, United States
  5. 5. Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Boston, MA, United States

Source: Immunotherapy Published:2016


Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several approaches of active and passive immunotherapy for EOC have been studied. The aim of this systematic review was to assess the clinical efficacy of specific immunotherapy in patients with EOC. We found 4524 references in seven databases and we included ten controlled clinical trials with 2285 patients with EOC reporting five active immunotherapeutic agents and three passive immunotherapies. Meta-analysis of six studies showed that overall there was not any significant difference in overall survival and recurrence-free survival between patients undergoing specific immunotherapy and those in control group. Most of the studies we evaluated reported a positive outcome from treatment with specific immunotherapy, although this was not significant. © 2016 Future Medicine Ltd.
Related Docs
1. Overview of Cd24 As a New Molecular Marker in Ovarian Cancer, Journal of Cellular Physiology (2019)
2. Cancer-Testis Antigens: A Novel Group of Tumor Biomarkers in Ovarian Cancers, International Journal of Cancer Management (2016)
Experts (# of related papers)
Akram Ghahghaei Nezamabadi (1)